Partners

xenogesis.jpg
 

XenoGesis Ltd., founded in 2011 by Dr. Richard Weaver, is a laboratory-based contract research organization (CRO) located in Nottingham, England UK specialized in preclinical DMPK, quantitative bioanalysis and expert interpretation. Dr. Weaver capitalizes on over 14 years of experience in multi-disciplinary drug discovery within large pharma. By combining  state-of-the-art in vitro, in vivo and bioanalytical capabilities with expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services, XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesized in drug discovery campaigns.

Together, Sekisui XenoTech and XenoGesis aim to provide collaborative, integrated and rational approached to DMPK studies within the ever-evolving framework of drug discovery and development. Our combined consultative approach to problem solving leads to increased flexibility, high content and quality and ultimately time and cost savings. The influence of DMPK is paramount for successful drug development, as these factors ultimately affect drug efficacy and safety. A holistic approach is crucial and serves as the foundation of this strategic partnership.

E-mail XenoGesis
 

Contact Us

Contact Us

Questions or inquiries? Use our contact form and we’ll reply as soon as possible.* indicates required field

Request A Quote
Request A Quote

Request A Quote

 Security code